Andreas Fouras

Entrepreneur, inventor, working at intersection of engineering and healthcare

[Andreas Fouras @AFouras]

I joined David Koch at TIP Group’s Emerging Wealth Winners Conference in Sydney to discuss 4DMedical’s clinical and commercial opportunity. We covered CT adoption, its ~$500m US market potential, and why it could reshape lung imaging.

Watch: https://t.co/4PwcCHcjS4

[Andreas Fouras @AFouras]

This week we hosted the @AustSharesAsso at @4DMedicalXV's Melbourne headquarters. We showcased our core technology CT:VQ the way clinicians experience it - through real clinical workflows, with insights from Matt Tucker, James Odgers & Prof Tim O’Meara $4DX

[Andreas Fouras @AFouras]

Today 4DMedical shares three major milestones.

1. Commercial milestone: GSK Partnership
2. Regulatory milestone: UK Clearance for CT™
3. Corporate milestone: S&P/ASX 200 Inclusion

ASX announcement: https://t.co/rgycUFMxTY

[Andreas Fouras @AFouras]

I had the opportunity to speak with investors about what it really takes to turn capital into meaningful market impact at TIP Group's Emerging Wealth Winners Conference in Sydney this week. These are the moments where innovation moves from promise to scale.

[TSN: The Stock Network @TheStockNet]

4DMedical (ASX:4DX) has delivered a transformational period, with the stock rising more than 2000%, underpinned by rapid clinical adoption, regulatory milestones and strong institutional support.

Ahead of presenting at @TIPGroup_Ltd Emerging Wealth Winners conference Founder, CEO and CTO, Dr Andreas Fouras speaks with The Stock Network’s @LelSmits about @4DMedicalXV's global expansion strategy and pathway to establishing CT:VQ™ as a new standard of care globally.

🌍 Transformational momentum and global validation
🇪🇺 Europe expansion and capital strategy
🫁 Commercial inflection and scaling economics
Watch the full interview ⚡ https://t.co/qnS0KCgvyV

🗓 Thursday, 16 April 2026
⏰ 8AM - 6PM
📍 Royal Randwick Racecourse, Sydney
Register now ⚡ https://t.co/5LExWNqgFf #4DX

[Andreas Fouras @AFouras]

This week I spoke at Impact Investment Summit APAC on the journey to disruption. It’s never a single breakthrough it’s building enduring companies with the right people, capital & ecosystem. AU now has the talent, research, and connectivity to turn innovation into global impact.

[Andreas Fouras @AFouras]

Spoke with Grady Wulff at Bell Potter on what’s driving 4DMedical: extracting more from standard lung scans no workflow change.

Now in leading US hospitals. CT:VQ™ is the only FDA-approved, injection-free lung blood flow scan gaining traction.

Watch: https://t.co/9HQmKfJfPc

[Andreas Fouras @AFouras]

Today we released our half-year report, a defining period for 4DMedical, showcasing execution, validation and growing global momentum. None of this is possible without the dedication of our incredible team.

Half year report: https://t.co/GwGS4gRniC

[Andreas Fouras @AFouras]

Australia is entering a once-in-a-generation moment for life sciences where solving real clinical problems isn’t just good science, it’s becoming one of the most powerful investment signals in the market.

@4DMedicalXV

[Andreas Fouras @AFouras]

_ @4DMedicalXV's commercial momentum is accelerating. UMiami has commenced clinical use of CT:VQ™, becoming the second U.S. academic medical centre after Stanford. We also confirm a two-year agreement with Lahey Hospital & Medical Center |
https://t.co/zH4JsuPKeK

[Andreas Fouras @AFouras]

Coming to you live from the @RSNA conference, I've just held an investor webinar outlining the significant progress @4DMedicalXV is making. Commercial traction across major segments and RSNA confirms the shift happening now. I’m excited about where we are and where we’re going.

[Andreas Fouras @AFouras]

This week at RSNA, @4DMedicalXV showcased the FDA-cleared CT:VQ™ the world’s first non-contrast perfusion imaging technology. CT:VQ™ delivers ventilation + perfusion from a standard chest CT with no contrast, no inhaled agents and no added scan time. https://t.co/5oZ2nSPTtj

[Andreas Fouras @AFouras]

4DMedical will be at RSNA this month, showcasing CT:VQ™ to the global radiology community. We’ll be meeting clinicians, partners and decision-makers, demonstrating how we help detect lung disease earlier and more precisely.

Learn more: https://t.co/xP8BbKjUCK

@4DMedicalXV

[Andreas Fouras @AFouras]

This week in Sydney, we shared how 4DMedical is enabling earlier detection and treatment of lung disease improving outcomes for patients & clinicians. Thanks to those who joined us, including John Hester (Bell Potter) & our CCO, Matt Tucker.

https://t.co/d1zl0us3rk
@4DMedicalXV

[Andreas Fouras @AFouras]

FY25 AGM reflected a year of strong execution & growing momentum for @4DMedicalXV

CT:VQ™ now FDA cleared, reimbursed & in use at Stanford Medicine, alongside expanding Lung Health Screening programs.

Chair Letter: https://t.co/ieiJ78rCmL
Q1 FY26 Report: https://t.co/agMuVMYzpM

[Andreas Fouras @AFouras]

_ @4DMedicalXV attended CHEST 2025 in Chicago, where our CT:VQ™ tech the world’s first to show lung perfusion without injection received a strong reception from US pulmonologists. Exciting momentum as we expand across the US!

Learn more about CHEST here: https://t.co/L8Rxy2wMXR

[Andreas Fouras @AFouras]

Exciting momentum for @4DMedical

@StanfordMed becomes the first U.S. AMC to adopt CT:VQ™ commercially, just weeks after FDA clearance. At the same time, our partnership with @AstraZeneca expands in Brazil to 5 new hospitals - 38,000 CT scans annually.

https://t.co/FaGZnVKjL4

[Andreas Fouras @AFouras]

Proud to see 4DMedical featured in the AFR among top Aussie techs with global potential.

“The next Pro Medicus,” says The Super Investor’s Paul Nojin.

We’re transforming respiratory diagnostics worldwide.

(AFR, sub req) https://t.co/IJkIXrhaNa

@4DMedicalXV @FinancialReview

[Andreas Fouras @AFouras]

September was a milestone month for 4DMedical (ASX:4DX) – $22.6m raised via options, $10m from Pro Medicus & $6m R&D rebate, taking pro forma cash to $45.5m. Strong backing fuels CT:VQ™ rollout, US expansion & RSNA 2025 prep.

ASX: https://t.co/GvQD4Kf9D4 @4DMedicalXV

[Andreas Fouras @AFouras]

4DMedical will hold its Annual General Meeting on Thursday, 30 Oct 2025 at 12pm AEDT at our Melbourne HQ.

We look forward to updating shareholders on progress and our vision ahead.

Notice of AGM: https://t.co/MP6LmSjEQ8
Annual report: https://t.co/kx0l2HlBnd
@4DMedicalXV